Savara Investors Urged to Lead Class Action Against Securities Fraud Allegations

Investors on Alert: Savara Inc. Faces Class Action Lawsuit

The Schall Law Firm has put out an important notice for investors of Savara Inc. This national litigation firm, known for its dedication to shareholder rights, has announced a class action lawsuit against Savara (NASDAQ: SVRA) due to serious allegations of securities fraud.

Key Details of the Lawsuit

The allegations relate to violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as well as Rule 10b-5 set by the U.S. Securities and Exchange Commission. This came into focus after investors who acquired Savara's securities between March 7, 2024, and May 23, 2025, reported significant losses amidst troubling revelations about the company’s practices. It is essential for all affected investors to take action before the deadline of November 10, 2025.

Why the Class Action is Happening

According to the complaint filed, Savara had allegedly made false and misleading statements to the market, particularly concerning its Biologics License Application (BLA) for MOLBREEVI. The complaint posits that the BLA failed to provide the FDA with adequate information concerning chemistry, controls, and manufacturing processes. It further states that the BLA, in its then-current form, stood a low chance of being approved, putting the company in a risky position that might necessitate a capital raise.

These misrepresentations have led to major vulnerabilities for investors, as when the truth about Savara’s BLA and practices came to light, it adversely affected their investments. This resulted in substantial damages to the investors involved.

Who Can Participate

If you suffer losses as a result of your investment in Savara during the aforementioned period, it is advisable to join this class action lawsuit. The Schall Law Firm encourages participants to reach out and discuss their potential involvement. Interested parties can contact Brian Schall at the firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. They can also phone at 310-301-3335 or visit www.schallfirm.com for more information.

The Next Steps

The class action is not yet certified, meaning that until such certification is granted, investors participating in this lawsuit are not represented by an attorney. It's critical that affected individuals make a timely decision on their participation; by doing nothing, they may miss out on potential recovery and remain as absent class members.

The Schall Law Firm has represented investors globally and specializes in securities class action lawsuits and shareholder litigation. This lawsuit serves as a reminder of the importance of vigilance in investment practices, particularly in volatile industries such as biotech.

The firm is also reminding stakeholders that this press release is considered attorney advertising in some jurisdictions, under applicable law and ethical guidelines.

As this class action unfolds, all eyes will be on Savara Inc. and how it navigates these significant allegations in the coming months.